3-D Sys Corp Del - DDD STOCK NEWS

3D Systems (NYSE:DDD) has launched its High Speed Fusion (HSF) industrial 3D printer platform, developed in collaboration with Jabil Inc. The new Roadrunner printer promises printing speeds three times faster than standard systems while achieving high precision. With capabilities for high-temperature materials, the marketplace for these solutions is valued at over $400 million. This innovation aims to cater to demanding sectors like aerospace and automotive, addressing previous limitations of high production costs and low throughput.

3D Systems (DDD) has delayed its fourth quarter and full year 2020 conference call, now set for March 2, 2021, after filing financial results on March 1, 2021. The company reaffirmed preliminary revenue expectations for Q4 2020 between $170M to $176M, and a GAAP operating loss ranging from $(8.6)M to $0.5M. Notably, the company may report internal control deficiencies, potentially indicating material weaknesses in its fiscal 2020 Annual Report.

3D Systems (NYSE: DDD) has been selected by Raytheon Technologies and the U.S. Army Research Laboratory to assist in a project aimed at optimizing additively manufactured parts for military applications. This innovative research will focus on improving heat transfer and overall system performance using 3D Systems' DMP Factory 500 metal 3D printing solution. The initiative aims to enhance the Army's modernization efforts by integrating advanced technologies in design, monitoring, and data security.

3D Systems (NYSE: DDD) is increasing its investment in regenerative medicine and bioprinting, driven by advancements with United Therapeutics. The collaboration aims to create 3D-printed lung scaffolds with vascularization to support living cells. Significant technology improvements enable broad applications in regenerative medicine, reducing reliance on animal testing for drug development. The company plans to expand resources in R&D and enhance its partner network, focusing on innovative applications that meet critical healthcare needs.

3D Systems (NYSE: DDD) announced the completion of the sale of its Cimatron and GibbsCAM software businesses for approximately $64 million, using part of the proceeds to repay its senior secured term loan, eliminating debt. The company reported strong preliminary Q4 2020 revenues expected between $170 million and $176 million, with over 20% organic growth in both Healthcare and Industrial units. Non-GAAP operating income is projected at $11-$19 million, significantly improving from Q4 2019. The firm will release detailed Q4 results on February 24, 2021.

3D Systems (NYSE:DDD) will present at the Needham Virtual Growth Conference on January 13, 2021, at 10:45 a.m. Eastern Time. A live webcast of the presentation will be accessible on the company's Investor Relations website and available for replay for 30 days after the event. The release includes forward-looking statements regarding potential risks and uncertainties that may affect future performance. For more details about 3D Systems and its additive manufacturing solutions, visit 3dsystems.com.

3D Systems (NYSE: DDD) has launched its Environmental, Social & Governance (ESG) initiative, reinforcing its commitment to global sustainability, social responsibility, and ethical governance. The initiative includes plans to reduce carbon emissions by optimizing manufacturing processes and advocating for sustainable practices. The company aims to achieve a lower environmental impact through additive manufacturing. Additionally, 3D Systems has committed to supporting social causes and maintaining high ethical standards within its operations.

3D Systems (NYSE: DDD) has appointed Dr. Vasant Padmanabhan to its Board of Directors, effective immediately. Dr. Padmanabhan brings nearly three decades of experience in R&D and operations, notably from his role as president of global R&D at Smith & Nephew. His expertise in the medical device sector is expected to support 3D Systems' focus on additive manufacturing in healthcare. Dr. Padmanabhan is enthusiastic about the company's transformation and innovation initiatives, which aim to enhance healthcare solutions.

3D Systems has received FDA 510(k) clearance for its Vantage® Ankle Patient-Specific Instrumentation (PSI), designed to streamline total ankle replacement surgeries. This product, developed in collaboration with Exactech, reduces the number of procedural steps and operation room time, enhancing overall surgical efficiency and soft-tissue preservation. The Vantage Ankle PSI offers a unique patient-specific approach, enabling direct osteotomies and better visualization of the surgical area. Full market availability is expected by late 2021 after a pilot launch.